Cohort Profile : The Haematological Malignancy Research Network (HMRN); a UK population-based patient cohort by Smith, Alexandra et al.
This is a repository copy of Cohort Profile : The Haematological Malignancy Research 
Network (HMRN); a UK population-based patient cohort.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/129316/
Version: Published Version
Article:
Smith, Alexandra orcid.org/0000-0002-1111-966X, Howell, Debra 
orcid.org/0000-0002-7521-7402, Crouch, Simon orcid.org/0000-0002-3026-2859 et al. (10 
more authors) (2018) Cohort Profile : The Haematological Malignancy Research Network 
(HMRN); a UK population-based patient cohort. International Journal of Epidemiology. 
ISSN 0300-5771 
https://doi.org/10.1093/ije/dyy044
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright 
exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy 
solely for the purpose of non-commercial research or private study within the limits of fair dealing. The 
publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White 
Rose Research Online record for this item. Where records identify the publisher as the copyright holder, 
users can verify any specific terms of use on the publisher’s website. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Cohort Profile
Cohort Profile: The Haematological Malignancy
Research Network (HMRN); a UK population-
based patient cohort
Alexandra Smith,1 Debra Howell,1 Simon Crouch,1 Dan Painter,1
John Blase,1 Han-I Wang,1 Ann Hewison,1 Timothy Bagguley,1
Simon Appleton,1 Sally Kinsey,2 Cathy Burton,3 Russell Patmore4 and
Eve Roman1*
1Department of Health Sciences, University of York, York, UK, 2Paediatric Haematology and Oncology
Unit, Leeds General Infirmary, 3St James’s Institute of Oncology, Leeds Teaching Hospitals NHS Trust,
Leeds, UK and 4Queens Centre for Oncology, Castle Hill Hospital, Cottingham, UK
*Corresponding author. Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York,
Seebohm Rowntree Building, Heslington, York YO10 5DD, UK. E-mail: eve.roman@york.ac.uk
Editorial decision 28 February 2018; Accepted 6 March 2018
Why was the cohort set up?
With diverse aetiologies, treatment pathways and outcomes,
haematological malignancies comprise a heterogeneous
group of over 60 cancers.1,2 Critically for epidemiology, ap-
preciation of the similarities and differences within this com-
plex cancer group only emerged in recent decades, as
understanding about the relationship between the various
haematological malignancies, the bone marrow, the immune
system and the cellular and genetic basis of malignant trans-
formation gradually increased. Integrating genetic data, with
information on morphology, immunology and clinical par-
ameters, the first World Health Organization (WHO) con-
sensus classification of haematological malignancies, which
is incorporated into the International Classification of
Diseases for Oncology (ICD-O3), was published in 2001.3
Since then, haemato-oncology has continued to be one of the
most rapidly evolving fields in cancer research, with ad-
vances in genomics and diagnostic technologies leading to
further WHO revisions.1,2,4–6 Unfortunately, however, al-
though these classification changes have been rapidly
adopted into clinical practice, the radical nature of the shift
has posed significant problems for population-based cancer
registries, with many struggling to capture data on new enti-
ties and continuing to report using the traditional ICD-10
groupings of leukaemia, Hodgkin lymphoma, non-Hodgkin
lymphoma and myeloma.7–11
Population-based data are required not only to inform
aetiological hypotheses and plan health care services, but
also to monitor the impact of therapeutic changes in the gen-
eral patient population. This need is particularly pertinent in
fast-moving areas like haemato-oncology where treatment
protocols are subject to rapid change, and ‘gold-standard’
randomized controlled trials (RCTs) are frequently restricted
to specific patient sub-groups: often younger patients with
fewer comorbidities.12–18 Furthermore, in some countries,
particularly those where universal health care is lacking, the
likelihood of trial entry often varies with socioeconomic sta-
tus, gender and ethnicity.19–23 Such biases impact on the ex-
ternal validity of RCTs, and ‘real-world’ observational data
are increasingly required to provide context and evaluate
treatment effectiveness across the whole patient popula-
tion.24–27
The Haematological Malignancy Research Network’s
[www.hmrn.org] population-based patient cohort was
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specifically established in the UK in 2004 to address the
needs outlined above by producing ‘real-time’, robust
generalizable data on haematological malignancies to in-
form contemporary clinical practice and research: lo-
cally, nationally and internationally.28 With core support
from Bloodwise [www.bloodwise.org.uk], formerly
Leukaemia and Lymphoma Research, HMRN is the re-
sult of a unique collaboration between university re-
searchers, National Health Service (NHS) clinicians and
patients/carers.
Who is in the cohort?
Established in September 2004, HMRN’s cohort was initi-
ated at a time when cancer care in England was co-
ordinated through a series of area-based Cancer Networks.
HMRN’s catchment covers two such adjacent Cancer
Networks: the Yorkshire Cancer Network and the
Humber & Yorkshire Coast Cancer Network. Health
geography changed in April 2013 when Cancer Networks
were incorporated into Strategic Clinical Networks, but
HMRN’s boundaries were not affected.
Patient care across the HMRN region is provided by a
unified clinical network that works to common guidelines
and operates across 14 hospitals, organized into five
multidisciplinary teams (MDTs) and a network-wide
paediatric oncology service (Figure 1A). Importantly, with
a population of around 3.8 million, the sociodemographic
structure of HMRN’s study area is broadly similar to the
UK as a whole (Figure 1B–D).
As a matter of policy, within HMRN all haematolo-
gical cancer diagnoses (whether originating from the
NHS or private sources, and irrespective of age, prognosis
and treatment intent) are reported and coded using the
latest WHO ICD-O classification by clinical haematopa-
thology specialists at the Haematological Malignancy
Diagnostic Service, HMDS [www.hmds.info]. Cited in
the Department of Health’s Cancer Reform Strategy as
the model for delivery of complex diagnostic services,
HMDS houses all of the relevant technology and expertise
required to diagnose and monitor haematological
cancers.29,30
Since September 2004, patients resident in the area have
entered HMRN’s cohort on the day that they are first diag-
nosed with a haematological neoplasm or precursor condi-
tion. The WHO diagnostic distribution (ICD-O3) for the
11-year period September 2004 to August 2015
(n¼ 26 423) is presented in Figure 2. The corresponding fre-
quencies and median ages at diagnosis are presented for
males and females separately for subtypes with 10 or more
diagnoses in Table 1; sex-rate ratios and 5-year relative sur-
vival estimates are also shown in Table 1. More information
about the classification of haematological malignancies is on
the study website [https://www.hmrn.org/about/classification].
Unlike other cancers, haematological neoplasms are
characterized by their ability to progress and transform;
follicular lymphoma to diffuse large B-cell lymphoma,
and myelodysplastic syndromes to acute myeloid leukae-
mia, for example.1,2,4 In Figure 2 and Table 1, patients
are counted as the number of diagnoses they have; during
the 11-year time frame, 24 859 (94.1%) patients had only
one diagnosis of a haematological malignancy or precur-
sor condition and 1564 (5.9%) patients had more than
one.
Figure 1. Haematological Malignancy Research Network (HMRN). A, Study location. B, Population age and sex distribution. C, Urban/rural distribu-
tion (Office of National Statistics definitions). D, Index of multiple deprivation (IMD): income domain.
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How often have they been followed up?
Patients enter the cohort when they are first diagnosed, and
their molecular diagnostic/prognostic data are linked to
clinical information in NHS medical records (paper and
electronic) around 7 months later. Subsequently, additional
linkages and abstractions are carried out, triggered either
by changes in state (e.g. death, disease progression, relapse,
treatment initiation) or requests for a clinical audit. All pa-
tients are ‘flagged’ at the national level for death and cancer
at the Medical Research Information Service (MRIS), and
routinely linked by NHS Digital to information contained
within nationwide health administrative databases. Deaths
are notified on a monthly basis, and linkages to cancer
registrations, as well as inpatient and outpatient Hospital
Episode Statistics (HES), are updated annually.
HMRN’s cohort has Section 251 support under the
NHS Act 2006. Operating in much the same way as a can-
cer registry, this enables all patients diagnosed within the
catchment to be registered and tracked through their care
pathways until death, regardless of consent. Importantly,
however, our procedures ensure that if at any point a pa-
tient dissents from data collection, all data relating to them
held on university servers are destroyed, and linked data
are no longer requested from NHS Digital.
In addition to core data collection and follow-up, a
number of studies have been nested within the HMRN co-
hort and others are planned for the future. Some of these
projects require more detailed information to be collected
from clinical records (specific events surrounding diagnosis
and deaths, for example), and others collect information
directly from consenting individuals at various points
along the patient pathway. All study leaflets and forms can
be found and downloaded from the website [https://www.
hmrn.org/resources/documents].
What has been measured?
Core data
Sociodemographic details are available for all patients,
with area-based population counts and measures of depriv-
ation being sourced from UK national data. In addition, in-
formation is obtained via linkage to routinely compiled
NHS health administrative databases; this includes inpa-
tient and outpatient hospital activity, as well as cancer
registrations (preceding and succeeding the index cancer
diagnosis) and death notifications.
Molecular diagnostic and prognostic data are available
for all points along the patient pathway where biological
samples (e.g. peripheral blood, bone marrow trephine/aspir-
ate, lymph node, cerebrospinal fluid) are taken for the pur-
poses of disease identification and monitoring. This
biological information, which varies with diagnostic cat-
egory, includes histology, immunohistochemistry, flow
cytometry, fluorescence in situ hybridization, next-gener-
ation sequencing and gene expression profiling. In addition
to these electronic data feeds, disease-specific templates are
used to abstract additional primary source data in the clin-
ical setting; the information collected includes individual
components of staging investigations, copies of scans, per-
formance scores and treatments (including stem cell trans-
plants), with response and outcome being recorded for all
episodes along the pathway. With a view to adhering as
Figure 2. Diagnostic distribution of haematological malignancies classified by ICD-O3; HMRN 2004–15.
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closely as possible to clinical trial standards in the real-
world setting, these data are abstracted according to tightly
controlled standard operating procedures, which include
consistency checks and periodic review. The data manual,
containing all form templates and instructions for data col-
lection, is on the study website [www.hmrn.org/resources].
Nested studies
HMRN was established with a view to providing the core
infrastructure into which additional projects could be
nested. Some of these projects have required more de-
tailed information to be collected from medical records at
particular points along the patient pathway. One such ex-
ample is the collection of more detailed information
about the routes to diagnosis of patients diagnosed with
mature B-cell neoplasms, and another relates to patient
management in the time leading to death. Other projects
collect information directly from consenting individuals;
core data are supplemented with information from vari-
ous sources, including questionnaires. For example,
around 4–8weeks after diagnosis, all patients who are
Table 1. Numbers, median ages, age-standardized (European 2013) rates, sex-rate ratios and 5-year relative survival (UK popu-
lation); HMRN 2004–15
Total
diagnoses
Median
age at
diagnosis
(years)
Annual
age-standardized
(European 2013)
rate per 100 000
(95% CI)
Sex-rate ratio
(male/female)
5-year relative
survival
All diagnoses (International Classification of Disease
for Oncology 3rd edition)
26 423 70.9 71.0 (70.7–71.3) 1.5 (1.5–1.5) 71.6 (70.9–72.4)
Total myeloid 6576 72.5 17.7 (17.6–17.9) 1.5 (1.5–1.6) 56.3 (54.7–57.9)
Acute myeloid leukaemia (9727, 9861, 9871, 9866,
9895, 9896, 9920)
1629 71.8 4.4 (4.3–4.4) 1.5 (1.5–1.6) 16.8 (14.7–19.1)
Acute promyelocytic leukaemia (9866) 112 50.0 0.3 (0.3–0.3) 1.1 (0.9–1.3) 64.3 (53.5–73.3)
Chronic myeloid leukaemia (9875) 408 59.4 1.1 (1.0–1.1) 1.5 (1.4–1.6) 89.8 (84.8–93.2)
Myelodysplastic syndromes (MDS) (9982–9986) 1494 75.8 4.1 (4.0–4.2) 2.5 (2.4–2.6) 30.2 (27.2–33.3)
Myelofibrosis (9961) 208 74.0 0.6 (0.6–0.6) 1.8 (1.6–2.0) 50.3 (40.4–59.4)
Myeloproliferative neoplasms (MPN) (9741, 9950,
9962, 9964, 9975)
2320 71.2 6.3 (6.2–6.3) 1.1 (1.0–1.1) 93.8 (91.4–95.5)
MDS/MPN (9945, 9946, 9975, 9876) 403 76.6 1.1 (1.1–1.2) 2.5 (2.3–2.7) 21.1 (15.9–26.8)
Total lymphoid 19 836 70.4 53.2 (53–53.5) 1.5 (1.5–1.5) 76.4 (75.6–77.3)
B-lymphoblastic leukaemia (9811–9816) 376 12.4 0.8 (0.8–0.9) 1.2 (1.1–1.3) 67.2 (61.7–72.1)
T-lymphoblastic leukaemia (9837) 104 17.6 0.2 (0.2–0.3) 2.1 (1.6–2.7) 64.7 (53.7–73.7)
Chronic lymphocytic leukaemia (9823) 2800 71.6 7.6 (7.5–7.7) 2.0 (2.0–2.1) 86.0 (83.7–88.0)
Hairy cell leukaemia (9940) 142 67.9 0.4 (0.4–0.4) 3.9 (3.3–4.5) 97.7 (53.9–99.9)
Myeloma (9732) 2749 73.0 7.5 (7.4–7.6) 1.7 (1.6–1.7) 48.5 (46.0–50.9)
Plasmacytoma (9731, 9734) 180 68.4 0.5 (0.5–0.5) 2.5 (2.2–2.9) 62.6 (52.7–71.0)
Extranodal marginal zone lymphoma (9699) 312 70.1 0.8 (0.8–0.9) 1.0 (0.9–1.1) 89.4 (82.8–93.6)
Systemic marginal zone lymphoma (9689) 1198 72.9 3.3 (3.2–3.3) 1.6 (1.6–1.7) 76.0 (72.1–79.4)
Follicular lymphoma (9690) 1310 65.0 3.5 (3.4–3.5) 1.0 (1.0–1.0) 87.5 (84.6–89.9)
Mantle cell lymphoma (9673) 340 74.0 0.9 (0.9–1.0) 2.5 (2.3–2.7) 43.8 (36.8–50.5)
Diffuse large B-cell lymphoma (9680) 3350 69.9 9.0 (8.9–9.1) 1.3 (1.3–1.3) 57.5 (55.5–59.4)
Burkitt lymphoma (9687) 143 53.0 0.4 (0.3–0.4) 3.8 (3.1–4.6) 51.0 (42.1–59.3)
Lymphoproliferative disorder NOS 823 77.0 2.2 (2.2–2.3) 1.6 (1.5–1.6) 81.8 (76.9–85.8)
Lymphocyte-predominant nodular Hodgkin
lymphoma (9659)
132 45.0 0.3 (0.3–0.4) 3.2 (2.6–3.9) 99.2 (76.1–100)
Classical Hodgkin lymphoma (9650) 1023 41.5 2.5 (2.5–2.6) 1.3 (1.3–1.4) 85.2 (82.3–87.7)
T-cell lymphoma (9837) 430 65.7 1.1 (1.1–1.2) 1.5 (1.4–1.6) 47.1 (41.6–52.4)
T-cell leukaemias (9831–9834) 178 73.6 0.5 (0.5–0.5) 1.0 (0.9–1.1) 85.4 (74.6–91.9)
Monoclonal B-cell lymphocytosis 1041 71.9 2.8 (2.8–2.9) 1.5 (1.5–1.6) 99.4 (80.0–100)
Monoclonal gammopathy of undetermined
significance (9765/1)
3168 72.9 8.7 (8.6–8.8) 1.4 (1.4–1.5) 90.5 (88.5–92.2)
NOS, not otherwise specified.
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well enough to provide informed consent (as assessed and
confirmed by a member of their clinical team) are sent
a study pack about HMRN and invited to complete a
survey about their symptoms before diagnosis and their
current quality of life (EQ-5D-5L). Those who agree are
sent further quality of life surveys at various intervals
thereafter.
What has it found? Key findings &
publications
HMRN’s maturing longitudinal data provide an increas-
ingly valuable resource with which to address real-world
questions of concern to researchers, clinicians, commis-
sioners, regulators and patients. Some of the key topics
tackled since the cohort’s inception are briefly described
below, and an up-to-date list of publications and reports is
provided on the study’s website [https://www.hmrn.org/
publications].
Descriptive epidemiology
The production and dissemination of high quality descrip-
tive information is a core aim of the project, and our first
paper on this topic provided annual incidence estimates for
24 main disease categories31: population-based rates strati-
fied by age, sex and socioeconomic status (as measured by
area-based deprivation/affluence), age-standardized
(European) rates, and estimated cases for the UK as a
whole. The analyses revealed distinctive age and gender pat-
terning for several myeloid and lymphoid subtypes, the
male rate being two to three times higher than the female
rate for several cancers, the differences being evident in
both children and adults. As the cohort has grown, increas-
ingly granular analyses have been conducted, revealing even
larger descriptive differences between subtypes, as well as
marked variations in overall and relative survival.32–34
Comparing patterns and trends is a general feature of
most descriptive epidemiological reports. Importantly, al-
though HMRN frequencies for most subtypes cannot be dir-
ectly compared with national programmes (where data are
coded to ICD-10, and progressions and transformations are
not always recorded), cross-checks with local cancer registries
have confirmed the superior quality of HMRN’s data.35
Furthermore, our incidence rates are in line with expectations
for subtypes where comparisons can be made; our acute leu-
kaemia and Hodgkin lymphoma rates, for example, [www.
hmrn.org] are broadly similar to the most recent estimates
published by SEER (Surveillance, Epidemiology and End
Results) and CRUK (Cancer Research UK).31–33,36
With respect to broader dissemination, the descriptive
section of our website has undoubtedly been one of the
cohort’s most important innovations, providing informa-
tion that cannot be found elsewhere [https://www.hmrn.
org/statistics]. The public pages provide up-to-date infor-
mation for researchers and clinicians on incidence, preva-
lence and relative survival; selection tools allow users to
pick specific disorders, stratify by age and sex and, for
measures of disease occurrence, aggregate subtypes. The
diagnosis and person-based tables that underpin the web-
site are updated annually and deaths are updated monthly.
At the time of writing (October 2017), the statistics are
based on 26 423 diagnoses occurring from September
2004 through August 2015, with all patients followed up
to May 2017.
Determinants of survival
HMRN’s data have reached the level of maturity required
to systematically investigate and monitor the many
sociodemographic, biological and treatment-related factors
that impact on outcome in the general patient population,
and this is a major focus of much of our current research.
Thus far, with a view to gaining insight into the general na-
ture of the relationship between age, deprivation and treat-
ment, we have examined the topic in two cancers. Both of
these are managed with standard therapy: the potentially
curable aggressive lymphoma (diffuse large B-cell lymph-
oma, DLBCL) and the currently incurable, but potentially
controllable, chronic myeloid leukaemia (CML). In the for-
mer, patient’s performance status was found to be more
predictive of survival than chronological age, with fitter
patients benefiting from intensive chemotherapy across all
ages.37 Furthermore, as with multiple myeloma,38 al-
though the survival of DLBCL patients who presented as
an emergency was poorer than that that of patients with
similar clinical characteristics who presented via other
routes,39 no associations between survival and socioeco-
nomic status were detected.37 Socioeconomic survival
inequalities have, however, been observed for CML.36
A once rapidly fatal cancer, it was transformed in the early
2000s into a long-term condition with a steadily rising
prevalence by the introduction of orally administered tyro-
sine kinase inhibitors (TKIs). Evidence suggests that in the
UK setting of universal health care, the survival inequalities
could be due to adherence issues. This contrasts with the
situation in countries like the USA, where lack of financial
resource for expensive drugs is the main driver of socioeco-
nomic inequality.
Patient pathways
HMRN’s core data, either linked to national datasets or
combined with further information from nested studies
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(e.g. self-reported material or details about care abstracted
from medical records), have enabled examination of pa-
tient experiences at various points on the pathway, both
preceding and succeeding diagnosis. Two important areas,
where evidence was needed to inform policy, are diagnostic
delay and end-of-life care. With respect to the former, our
analysis confirmed: prolonged time to diagnosis among
some disease subtypes (e.g. myeloma) but not others
(e.g. acute leukaemia); commonality in certain symptoms
across diseases (e.g. pain and fatigue), but specificity
within others (e.g. lymphadenopathy in lymphomas, bleed-
ing and bruising in acute leukaemias); and that whereas
some symptoms were frequently reported but absent from
national guidance, others were included but rarely re-
ported by patients.40
Our work on the latter part of the pathway developed in
response to concerns about the lack of integration between
haematology and specialist palliative care (SPC) services,41
and the greater propensity for hospital death among
haematology patients.42 The nested studies examining these
areas revealed that around half of patients had at least one
SPC referral, with the likelihood of referral increasing with
duration of survival and varying by subtype, being most fre-
quent in myeloma and least in acute leukaemia.43 Hospital
deaths were common despite subtype (indolent or aggres-
sive), occurring most frequently in patients dying within
3 months of diagnosis.44 Less than half of patients took
part in a discussion about their end-of-life preferences, with
those who did not being significantly more likely to die in
hospital. Of those who did have a discussion, a quarter
stated a preference to remain in hospital at the time of their
death,45 a much higher proportion than reported in studies
including patients with other conditions.46 Our nested
qualitative studies found that such differences are due to
the close relationship between haematology staff and their
patients, and that uncertain disease trajectories (i.e. charac-
terized by sudden, unexpected deterioration and rapid
death), are also important.47
Health economics
The continued emergence of new approaches to diagnosis
and treatment mean that haematological malignancies are
among the most expensive cancers to treat, consistently
coming in the top three of most economically developed
countries’ cancer spend lists.48–50 However, in the past
most of the evidence on treatment costs and health-related
quality of life (HRQoL) has emanated either from single
institutions or from clinical trials, which are often select-
ive, with poor generalizability to the patient population as
a whole. Hence, it is now recognized that appraisals re-
quire information about the likely impact in ‘real-world’
settings, an area in which our longitudinal data are making
meaningful contributions.51,52
What are the main strength and
weaknesses?
HMRN’s major strengths include its large well-defined
catchment area, centralized world-class diagnostics, com-
pleteness of case ascertainment, adherence to National
treatment guidelines, and detailed follow-up of all patients.
All of these combine to ensure that the patient cohort is
not affected by the data quality issues faced by many
population-based cancer registries. Predicated on infra-
structures within the NHS, where universal health care is
freely provided on the basis of clinical need, HMRN occu-
pies a unique forefront position in relation to the provision
of real-time data concerning the impact of diagnostic and
treatment developments.
With respect to limitations, although most haematolo-
gical malignancies exhibit comparatively little geo-
graphical variation, a few are regionally very specific. The
most well-known examples are: adult T-cell leukaemia/
lymphoma (ATLL), which develops in approximately 5%
of those infected with the RNA virus HTLV-1 that is en-
demic to parts of Japan, South America, Papua New
Guinea, Africa and the Middle East; and African endemic
Burkitt lymphoma, which is largely restricted to the
malarial belts of equatorial Africa, Papua New Guinea,
and parts of South Amerca. Clearly HMRN data cannot be
used to investigate these subtypes. Furthermore, although
HMRN’s patient cohort can be used to answer many
important questions, the absence of a comparison cohort
of unaffected individuals impacts on investigations requir-
ing background rates of comorbidity and/or procedures.
This is, however, currently being rectified; an anonymized
comparison cohort, comprising 10 age-, sex- and region of
residence-matched individuals per patient, has recently
been selected from primary care registers and linked to the
same administrative databases as the patients (HES, cancer
and death). The methods and outputs for this project will
be described in a future report.
Can I get hold of the data? Where can I find
out more?
Although ethical permissions and agreements with pro-
viders of national data mean that potentially identifiable
data cannot be transferred or accessed off site, HMRN
data are contributing to several ongoing research projects.
For information on how to collaborate with HMRN re-
searchers and investigate questions of interest, please e-
mail [enquiries@hmrn.org]. Additional contact details are
provided on the website [www.hmrn.org.]
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